The brilliance of discovery
Nobel Prize awarded for the discovery of conducting polymers
Initial patents filed on Sirigen technology (conducting polymer biosensors)
Sirigen founded by Professor Guillermo C. Bazan, Dr. Brent S. Gaylord, and Mr. Patrick J. Dietzen
Awarded First place in the business plan competition at the University of California Santa Barbara (UCSB)
Mr. James B. McCarthy becomes first investor in Sirigen and joins the company's board of directors
Completion of friends initial financing (convertible notes)
Corporate office and laboratory facility established in Santa Barbara, CA
Secured exclusive worldwide licenses on seven patents from UCSB
Awarded $2,100,000 three year grant from the U.S. Army and the ICB
CRADA agreement signed with the U.S. Dept. of Agriculture
Dr. N A Kerton joins the Board
Closing of Series A funding completed
Sirigen files patent “Fluorescent Methods and Materials for Directed Biomarker Signal Amplification”
Closed first Commercial deal
24 April 2008
Closed Series B funding from Seraphim Capital and Oxford Capital Partners
Sirigen Group Ltd became the new legal identity
Headquarters established in Dorset, UK
Move from Santa Barbara to San Diego
Sirigen opens new Headquarters in Ringwood, Hampshire, UK
Sirigen inks commercial deals for Project Green
Seraphim Capital Fund and Oxford Capital Partners invest further £1.2 million in Sirigen
Major development deal signed in flow cytometry
Second flow cytometry partner signed up for reagent development
IQ Capital, the National Endowment for Science, Technology, and the Arts (NESTA), and YFM Private Equity complete two financing rounds along with existing investors Seraphim Capital and Oxford Capital Partners.
David Evans (former CFO of Shield Diagnostics and chairman and non-executive director at a number of diagnostic and life science companies) was appointed chairman of the board and Arthur Cole (former executive vice president of Visible Genetics and vice president of new business development at Pharmacia Biotech) was appointed as a non-executive director.
First BV421™-conjugated (antibody) products launched commercially by BioLegend Inc.
Two flow cytometry abstracts and a poster (#287) presented at Cyto2011 (XXVI Congress of the International Society for the Advancement of Cytometry) in Baltimore.
First BV570™-conjugated (antibody) products launched commercially by BioLegend Inc.
Further funding round completed successfully.
First BV421™-conjugated (antibody) products launched commercially by BD.
First BV605™- and BV650™-conjugated (antibody) products launched commercially by BioLegend Inc.
Article ‘Brilliant Violet Fluorophores: A New Class of Ultrabright Fluorescent Compounds for Immunofluorescence Experiments’, Chattopadhyay et al accepted for publication in Cytometry A (accompanied by Editorial Comment).
First BV711™- and BV785™- conjugated (antibody) products launched commercially by BioLegend Inc..
First BV605™- conjugated (antibody) products launched commercially by BD Bioscience.
BD Bioscience buys Sirigen Group Limited
(read press release)